Last reviewed · How we verify
heptavalent pneumococcal conjugate vaccine, Prevenar
heptavalent pneumococcal conjugate vaccine, Prevenar is a Conjugate vaccine Biologic drug developed by Heinrich-Heine University, Duesseldorf. It is currently in Phase 3 development for Prevention of invasive pneumococcal disease caused by seven serotypes of Streptococcus pneumoniae.
Prevenar stimulates the body's immune system to produce antibodies against pneumococcal disease.
Prevenar stimulates the body's immune system to produce antibodies against pneumococcal disease. Used for Prevention of invasive pneumococcal disease caused by seven serotypes of Streptococcus pneumoniae.
At a glance
| Generic name | heptavalent pneumococcal conjugate vaccine, Prevenar |
|---|---|
| Sponsor | Heinrich-Heine University, Duesseldorf |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The heptavalent pneumococcal conjugate vaccine, Prevenar, works by introducing antigens from seven serotypes of Streptococcus pneumoniae to the body, which triggers an immune response and the production of antibodies. These antibodies help to neutralize the bacteria and prevent infection. The vaccine is designed to provide protection against invasive pneumococcal disease, such as meningitis and sepsis, as well as non-invasive diseases like pneumonia.
Approved indications
- Prevention of invasive pneumococcal disease caused by seven serotypes of Streptococcus pneumoniae
Common side effects
- Pain, redness, or swelling at the injection site
- Fever
- Irritability
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (PHASE1)
- A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
- A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- heptavalent pneumococcal conjugate vaccine, Prevenar CI brief — competitive landscape report
- heptavalent pneumococcal conjugate vaccine, Prevenar updates RSS · CI watch RSS
- Heinrich-Heine University, Duesseldorf portfolio CI
Frequently asked questions about heptavalent pneumococcal conjugate vaccine, Prevenar
What is heptavalent pneumococcal conjugate vaccine, Prevenar?
How does heptavalent pneumococcal conjugate vaccine, Prevenar work?
What is heptavalent pneumococcal conjugate vaccine, Prevenar used for?
Who makes heptavalent pneumococcal conjugate vaccine, Prevenar?
What drug class is heptavalent pneumococcal conjugate vaccine, Prevenar in?
What development phase is heptavalent pneumococcal conjugate vaccine, Prevenar in?
What are the side effects of heptavalent pneumococcal conjugate vaccine, Prevenar?
Related
- Drug class: All Conjugate vaccine drugs
- Manufacturer: Heinrich-Heine University, Duesseldorf — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of invasive pneumococcal disease caused by seven serotypes of Streptococcus pneumoniae
- Compare: heptavalent pneumococcal conjugate vaccine, Prevenar vs similar drugs
- Pricing: heptavalent pneumococcal conjugate vaccine, Prevenar cost, discount & access